LLY vs MNKD: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: MNKD is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LLY and MNKD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LLY and MNKD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.

Full LLY guide

MannKind Corporation is a biopharmaceutical company built around its proprietary Technosphere dry-powder inhalation platform and, more recently, endocrine and rare-disease products. Its best-known product is Afrezza, an inhaled mealtime insulin for diabetes, but the larger financial driver has become royalty revenue from Tyvaso DPI, a dry-powder inhaled treatment for pulmonary arterial hypertension and pulmonary fibrosis that United Therapeutics markets under a partnership using MannKind's inhalation technology. MannKind also markets Furoscix, an at-home subcutaneous furosemide therapy for fluid overload associated with conditions like heart failure, which has been ramping quickly. This mix of a growing royalty stream plus its own commercial products distinguishes MannKind from pre-revenue biotechs.

Full MNKD guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.
• MNKD drivers: Tyvaso DPI royalties; Furoscix and Afrezza commercial products.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: LLY trades at a premium valuation, so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. For MNKD, the dominant risk is concentration and dependence on partners and catalysts: a large share of high-margin revenue comes from Tyvaso DPI royalties controlled by United Therapeutics, so any slowdown, competition, or change in that product's trajectory would hit MannKind directly.

Pick LLY if you believe its drivers more; MNKD if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LLY and MNKD guides.

LLY. Eli Lilly trades at a premium pharma multiple that prices in continued rapid growth from the obesity and diabetes franchise plus pipeline optionality. The valuation debate centers on how large, durable, and profitable the incretin market proves to be and how competition (chiefly Novo Nordisk and emerging oral incretins) shapes pricing and share. Figures are approximate and should be verified against the latest filings before drawing conclusions.

MNKD. These figures are approximate and tied to the asOf date; verify live numbers before acting. MannKind is valued as a catalyst-driven biopharma, so its shares hinge on the durability of Tyvaso DPI royalties plus the success of product launches and pipeline readouts rather than a stable earnings multiple. Binary regulatory and clinical events can move the stock sharply, so judge it on catalysts and cash runway as much as current revenue.

Headline figures (approximate, early 2026): LLY shows revenue (ttm) ~$45 to 55 billion and growing fast (verify), operating margin ~30%+ (verify), gross margin ~80% (typical for branded pharma), p/e (ttm) ~40x to 60x (premium; verify); MNKD shows revenue trend Q1 2026 total revenue around $90 million, up roughly 15% year over year, revenue drivers Tyvaso DPI royalties (~$33M), Afrezza (~$15M), and Furoscix (~$15.5M) in Q1 2026, profitability Reported a net loss in Q1 2026 while investing in growth; profitability is not yet consistent, ambition Management has pointed to a roughly $450 million revenue run-rate goal supported by launches and catalysts.

LLY and MNKD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined LLY and MNKD exposure against your real portfolio. It is not an investment adviser.